Stock UBM ULISSE BIOMED S.P.A.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Ulisse Biomed S.p.A.

Equities

UBM

IT0005451213

Market Closed - Borsa Italiana
Other stock markets
 11:44:59 2024-05-31 am EDT 		5-day change 1st Jan Change
1.15 EUR 0.00% Intraday chart for Ulisse Biomed S.p.A. +1.32% -30.51%
May. 27 Ulisse Biomed, agreement with Elettrobiochimica for IVDR kit development AN
May. 20 Ulisse Biomed S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
ULISSE BIOMED S.P.A. Stock Ulisse Biomed S.p.A.
-30.51% 27.19M -
MODERNA, INC. Stock Moderna, Inc.
+46.87% 58.06B
B-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-6.33% 40.53B
B
LONZA GROUP AG Stock Lonza Group AG
+37.52% 38.99B
A
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.90% 26.7B
B-
CELLTRION, INC. Stock Celltrion, Inc.
-12.01% 26.56B
C
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.69% 18.98B
B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.58% 12.17B
B+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+23.22% 12B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+25.00% 11.92B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. UBM Stock
  4. Ratings Ulisse Biomed S.p.A.